ArticleThe oncologist2026
Patterns of progression and survival in patients with mismatch repair deficient/ microsatellite instability- high metastatic colorectal cancer treated with immunotherapy.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Resistance Phenotypes and Treatment Sequencing After Immune Checkpoint Blockade in MSI-H/dMMR Metastatic Colorectal Cancer: A Review.Journal of gastrointestinal cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunotherapy has shown to be efficacious in patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer (CRC). Unfortunately, there is still a population of patients who either do not respond or progress after prior response. Understanding the progression dynamics and outcomes based on the nature of disease progression (PD) is critical in this patient population.
methodsWe performed a retrospective analysis of 166 patients with advanced dMMR/MSI-H CRC who received immunotherapy. PD patterns were classified as intrinsic (progression at first restaging scan) or adaptive (progression after initial stable/responding disease) and as single organ or systemic.
resultsProgression was seen in 64 patients (38.6%) with single organ progression in 31 (48.4%) and systemic progression in 33 (51.5%). Intrinsic progression was seen in 32 patients (50%) and adaptive progression in 32 (50%). Patients with single organ progression had a longer median TTP (mTTP) and median OS (mOS) compared to patients with systemic progression (mTTP: 8.8 vs 4.0 months, P = .005; mOS: 65.9 vs 18.7 months, P = .023). Patients with adaptive PD had a longer mTTP and mOS compared to patients with intrinsic PD (mTTP: 11.6 vs 1.9 months, P = <.01; mOS: 65.9 months vs 17.0 months, P = .001).
conclusionThis analysis identifies significant differences in outcomes of patients with dMMR/MSI-H CRC based on the pattern and extent of progression, underscoring the need for tailored therapeutic strategies depending on the nature of PD-1-based progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.